In analyses restricted to IDH-wildtype gliomas, the pooled CSF detection rate was 87% (95% CI 55–97; I2 = 71.4%) for intracranial sampling (Figure 5A) and 73% (95% CI 64–79; I2 = 42.5%) for lumbar puncture (Figure 5B). This evidence concerns the gene IDH2 and central nervous system cancer.